Literature DB >> 11298328

Clonal Th2 cells associated with chronic hypereosinophilia: TARC-induced CCR4 down-regulation in vivo.

A de Lavareille1, F Roufosse, L Schandené, P Stordeur, E Cogan, M Goldman.   

Abstract

We analyzed the expression of chemokine receptors on clonal Th2-type CD4(+)CD3(- )lymphocytes isolated from blood of two patients with chronic hypereosinophilia. First, we observed that these Th2 cells express membrane CCR5 and CXCR4 but neither CCR3 nor CCR4 when analyzed immediately after purification. However, CCR4 appeared following culture in human serum-free medium, suggesting that it was down-regulated in vivo. Indeed, patient's serum, but not control human serum, strongly down-regulated CCR4 expression on cultured Th2 cells. As high levels of TARC, a CCR4 ligand, were detected in the serum of four hypereosinophilic patients with CD3(-)CD4(+) clonal Th2 cells, we evaluated the effect of TARC neutralization in this system. Addition of a neutralizing anti-TARC mAb inhibited CCR4 down-regulation by patient's serum, indicating that circulating TARC contributed to CCR4 down-regulation on Th2 cells in vivo. Clonal Th2 cells did not secrete high levels of TARC themselves but induced a sustained production of TARC by monocyte-derived dendritic cells, a phenomenon that was inhibited by addition of blocking mAb against IL-4 receptor. We conclude that high circulating levels of TARC in serum of patients with chronic hypereosinophilia, most likely derived from antigen-presenting cells stimulated by Th2-type cytokines, induce down-regulation of CCR4 on Th2 cells in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11298328     DOI: 10.1002/1521-4141(200104)31:4<1037::aid-immu1037>3.0.co;2-#

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome.

Authors:  P Khoury; P Zagallo; C Talar-Williams; C S Santos; E Dinerman; N C Holland; A D Klion
Journal:  Allergy       Date:  2012-07-09       Impact factor: 13.146

Review 2.  Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations.

Authors:  Florence Roufosse
Journal:  Haematologica       Date:  2009-09       Impact factor: 9.941

3.  Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs.

Authors:  Verena Semmling; Veronika Lukacs-Kornek; Christoph A Thaiss; Thomas Quast; Katharina Hochheiser; Ulf Panzer; Jamie Rossjohn; Patrick Perlmutter; Jia Cao; Dale I Godfrey; Paul B Savage; Percy A Knolle; Waldemar Kolanus; Irmgard Förster; Christian Kurts
Journal:  Nat Immunol       Date:  2010-02-28       Impact factor: 25.606

4.  Expression of T lymphocyte chemoattractants and activation markers in vernal keratoconjunctivitis.

Authors:  A M Abu El-Asrar; S Struyf; S A Al-Kharashi; L Missotten; J Van Damme; K Geboes
Journal:  Br J Ophthalmol       Date:  2002-10       Impact factor: 4.638

5.  Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection.

Authors:  Stephen P Matthews; John S Tregoning; Anthony J Coyle; Tracy Hussell; Peter J M Openshaw
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

Review 6.  What does elevated TARC/CCL17 expression tell us about eosinophilic disorders?

Authors:  Julien Catherine; Florence Roufosse
Journal:  Semin Immunopathol       Date:  2021-05-19       Impact factor: 9.623

7.  Clinical and Biological Markers in Hypereosinophilic Syndromes.

Authors:  Paneez Khoury; Michelle Makiya; Amy D Klion
Journal:  Front Med (Lausanne)       Date:  2017-12-22

Review 8.  Neutralizing endogenous chemokines with small molecules. Principles and potential therapeutic applications.

Authors:  Jean-Luc Galzi; Muriel Hachet-Haas; Dominique Bonnet; Francois Daubeuf; Sandra Lecat; Marcel Hibert; Jacques Haiech; Nelly Frossard
Journal:  Pharmacol Ther       Date:  2010-02-01       Impact factor: 12.310

9.  Furin-dependent CCL17-fused recombinant toxin controls HTLV-1 infection by targeting and eliminating infected CCR4-expressing cells in vitro and in vivo.

Authors:  Masateru Hiyoshi; Kazu Okuma; Seiji Tateyama; Kazuya Takizawa; Masumichi Saito; Madoka Kuramitsu; Kumiko Araki; Kazuhiro Morishita; Seiji Okada; Naoki Yamamoto; Arya Biragyn; Kazunari Yamaguchi; Isao Hamaguchi
Journal:  Retrovirology       Date:  2015-08-20       Impact factor: 4.602

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.